Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Faivre

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Apoptosis : an International Journal on Programmed Cell Death|October 27, 2004
Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinomaD Aguirre, P Boya, D Bellet, et al.
British Journal of Cancer|July 20, 2007
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cellsM Serova, C M Galmarini, A Ghoul, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|April 1, 1997
Long-term follow-up after adjuvant chemotherapy in completely resected early stage ovarian carcinomaE Raymond, Y Drolet, L Marpeau, et al.
British Journal of Cancer|November 27, 2008
Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cellsK A Benhadji, M Serova, A Ghoul, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2002
Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinomaS Faivre, T Le Chevalier, C Monnerat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2003
Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastomaE Raymond, M Fabbro, V Boige, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2002
Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancerE Raymond, W W ten Bokkel Huinink, J Taïeb, et al.
Bulletin Du Cancer|October 2, 2009
[Basaloid squamous cell carcinomas of the head and neck]J Thariat, C Badoual, C Faure, et al.
Molecular Pharmacology|October 20, 2000
Oxaliplatin-induced damage of cellular DNAJ M Woynarowski, S Faivre, M C Herzig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2000
Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patientsJ Alexandre, P Bleuzen, J Bonneterre, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Apoptosis : an International Journal on Programmed Cell Death|October 27, 2004
Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinomaD Aguirre, P Boya, D Bellet, et al.
British Journal of Cancer|July 20, 2007
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cellsM Serova, C M Galmarini, A Ghoul, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|April 1, 1997
Long-term follow-up after adjuvant chemotherapy in completely resected early stage ovarian carcinomaE Raymond, Y Drolet, L Marpeau, et al.
British Journal of Cancer|November 27, 2008
Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cellsK A Benhadji, M Serova, A Ghoul, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2002
Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinomaS Faivre, T Le Chevalier, C Monnerat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2003
Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastomaE Raymond, M Fabbro, V Boige, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2002
Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancerE Raymond, W W ten Bokkel Huinink, J Taïeb, et al.
Bulletin Du Cancer|October 2, 2009
[Basaloid squamous cell carcinomas of the head and neck]J Thariat, C Badoual, C Faure, et al.
Molecular Pharmacology|October 20, 2000
Oxaliplatin-induced damage of cellular DNAJ M Woynarowski, S Faivre, M C Herzig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2000
Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patientsJ Alexandre, P Bleuzen, J Bonneterre, et al.
Pageof 7